Skip to content
value.today
Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc.

🇺🇸 Waltham, Massachusetts, USABiotechnologyFounded 2017
Total raised
$116 M
1 round on record
Latest round
$116 M
Aug 2020
First round on record
Aug 2020
Today
Went public
See the company page

Dyne Therapeutics, Inc. is listed today as Dyne Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Dyne Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2020$116 MNo. 1$50 to $250 million

Dyne Therapeutics, Inc.: Raise no. 1, Aug 2020

Investors in this round

19 investors had bought by the notice of Aug 14, 2020: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 22 investors are named for Dyne Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$116 M of $116 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jonathan McNeill, M.D. · Executive Officer
  • Joshua Brumm · Executive Officer, Director
  • Oxana Beskrovnaya, Ph.D. · Executive Officer
  • Richard Scalzo · Executive Officer
  • Romesh Subramanian, Ph.D. · Executive Officer
  • Catherine Stehman-Breen, M.D. · Director
  • David Lubner · Director
  • Dirk Kersten · Director
  • Edward Hurwitz · Director
  • Jason Rhodes · Director
  • Lawrence Klein, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joshua Brumm, President and Chief Executive Officer. Newest notice filed Aug 14, 2020. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Dyne Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2020).

    SEC Form D · Aug 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2020

Products and services#

No products or services of Dyne Therapeutics, Inc. are on record.

Investors#

22 named in official filings. Open an investor to see everything it has backed.

Investors in Dyne Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Atlas Venture Associates Opportunity I, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Atlas Venture Associates Opportunity I, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Atlas Venture Associates XI, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Atlas Venture Associates XI, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Atlas Venture Fund XI, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Atlas Venture Opportunity Fund I, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Catherine Stehman-BreenPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2020)SEC Form 3
CureDuchenne Ventures, LLCVenture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
David Charles LubnerPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2020)SEC Form 3
Forbion Capital Fund IV Cooperatief U.A.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Lawrence Otto KleinPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2020)SEC Form 3
Logos Global Management LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
MPM Asset Management Investors BV2018 LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
MPM Bioventures 2018 (B), L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
MPM BioVentures 2018 GP LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
MPM BioVentures 2018 LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
MPM Bioventures 2018, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Vida Ventures II-A, LLCVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Vida Ventures II, LLCVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
VV Manager II, LLCOthernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Largest shareholders today

Institutions holding Dyne Therapeutics, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Dyne Therapeutics, Inc.
NameRoleNamed in
Jonathan McNeill, M.D.Executive officerAug 2020
Joshua BrummExecutive officerAug 2020
Oxana Beskrovnaya, Ph.D.Executive officerAug 2020
Richard ScalzoExecutive officerAug 2020
Romesh Subramanian, Ph.D.Executive officerAug 2020
Catherine Stehman-Breen, M.D.DirectorAug 2020
David LubnerDirectorAug 2020
Dirk KerstenDirectorAug 2020
Edward HurwitzDirectorAug 2020
Jason RhodesDirectorAug 2020
Joshua BrummDirectorAug 2020
Lawrence Klein, Ph.D.DirectorAug 2020

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.